(VIANEWS) – BanColombia S.A. (CIB), Laredo Petroleum (LPI), Neurocrine Biosciences (NBIX) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. BanColombia S.A. (CIB)

119% sales growth and 17.84% return on equity

Bancolombia S. A. offers a variety of banking services and products to individuals and corporations in Colombia, Panama and Puerto Rico.

BanColombia S.A.’s sales growth this year is anticipated to be 85.3% and 12.4% for next year.

Year-on-year quarterly revenue growth grew by 81.9%, now sitting on N/A for the twelve trailing months.

Volume

Today’s last reported volume for BanColombia S.A. is 643015 which is 67.36% above its average volume of 384192.

BanColombia S.A.’s sales growth for the next quarter is 119%. The company’s growth estimates for the ongoing quarter and the next is 126.7% and 296.7%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.84%.

Volatility

BanColombia S.A.’s last day, last week, and last month’s current intraday variation average was 0.64%, 2.13%, and 2.86%, respectively.

BanColombia S.A.’s highest amplitude of average volatility was 1.79% (day), 2.37% (last week), and 3.27% (last month), respectively.

BanColombia S.A.’s Stock Yearly Top and Bottom Value

BanColombia S.A.’s stock is valued at $37.50 at 16:22 EST, way below its 52-week high of $45.98 and way higher than its 52-week low of $27.64.

BanColombia S.A.’s Moving Average

BanColombia S.A.’s value is below its 50-day moving average of $40.04 and above its 200-day moving average of $36.10.

2. Laredo Petroleum (LPI)

42% sales growth and 58.91% return on equity

Laredo Petroleum, Inc., a separate energy company, is involved in the acquisition, exploration, development, and maintenance of natural gas properties within the Permian basin of West Texas, USA.

Laredo Petroleum’s sales growth this year is anticipated to be 16.7% and 8.4% for next year.

Year-on-year quarterly revenue growth grew by 150%, now sitting on 1.39B for the twelve trailing months.

Volume

Today’s last reported volume for Laredo Petroleum is 1931770 which is 126.6% above its average volume of 852476.

Laredo Petroleum’s sales growth for the next quarter is 42%. The company’s growth estimates for the current quarter and the next is 358.5% and 338.6%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 58.91%.

Volatility

Laredo Petroleum’s last day, last week, and last month’s current intraday variation average was 9.57%, 7.01%, and 5.54%, respectively.

Laredo Petroleum’s highest amplitude of average volatility was 12.03% (day), 9.27% (last week), and 8.61% (last month), respectively.

Laredo Petroleum’s Stock Yearly Top and Bottom Value

Laredo Petroleum’s stock is valued at $81.47 at 16:22 EST, way under its 52-week high of $120.86 and way above its 52-week low of $36.25.

Laredo Petroleum’s Moving Average

Laredo Petroleum’s value is above its 50-day moving average of $80.67 and way higher than its 200-day moving average of $74.01.

3. Neurocrine Biosciences (NBIX)

19.2% sales growth and 5.5% return on equity

Neurocrine Biosciences, Inc. is a neuropharmaceutical company that focuses on neuroscience. It develops, delivers, and tests treatments for neurological, endocrine, or psychiatric conditions.

Neurocrine Biosciences’s sales growth this year is expected to be 21.9% and 16.2% for next year.

Year-on-year quarterly revenue growth grew by 31.3%, now sitting on 1.21B for the twelve trailing months.

Volume

Today’s last reported volume for Neurocrine Biosciences is 829160 which is 12.6% above its average volume of 736334.

Neurocrine Biosciences’s sales growth for the next quarter is 19.2%. The company’s growth estimates for the current quarter and the next is 37.2% and 169.6%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.5%.

Volatility

Neurocrine Biosciences’s last day, last week, and last month’s current intraday variation average was 0.58%, 1.43%, and 1.43%, respectively.

Neurocrine Biosciences’s highest amplitude of average volatility was 1.53% (day), 2.68% (last week), and 3.23% (last month), respectively.

Neurocrine Biosciences’s Stock Yearly Top and Bottom Value

Neurocrine Biosciences’s stock is valued at $97.30 at 16:22 EST, below its 52-week high of $108.02 and way above its 52-week low of $71.88.

Neurocrine Biosciences’s Moving Average

Neurocrine Biosciences’s worth is higher than its 50-day moving average of $91.60 and higher than its 200-day moving average of $90.06.

4. Charles River Laboratories (CRL)

17.6% sales growth and 18.37% return on equity

Charles River Laboratories International, Inc. is an early-stage contract-research company that provides services for drug discovery, safety testing, and non-clinical research.

Charles River Laboratories’s sales growth this year is expected to be 22.2% and 11.9% for next year.

Year-on-year quarterly revenue growth grew by 20.5%, now sitting on 3.43B for the twelve trailing months.

Volume

Today’s last reported volume for Charles River Laboratories is 337564 which is 38.27% below its average volume of 546850.

Charles River Laboratories’s sales growth for the next quarter is 17.6%. The company’s growth estimates for the ongoing quarter and the next is 10.7% and 7.9%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.37%.

Volatility

Charles River Laboratories’s last day, last week, and last month’s current intraday variation average was 5.13%, 2.72%, and 2.71%, respectively.

Charles River Laboratories’s highest amplitude of average volatility was 5.91% (day), 3.88% (last week), and 3.58% (last month), respectively.

Charles River Laboratories’s Stock Yearly Top and Bottom Value

Charles River Laboratories’s stock is valued at $226.16 at 16:22 EST, below its 52-week low of $237.27.

Charles River Laboratories’s Moving Average

Charles River Laboratories’s value is way under its 50-day moving average of $393.86 and way below its 200-day moving average of $371.52.

5. W.P. Carey REIT (WPC)

11.8% sales growth and 7.07% return on equity

W. P. Carey ranks among the largest net lease REITs with an enterprise value of approximately $18 billion and a diversified portfolio of operationally-critical commercial real estate that includes 1,215 net lease properties covering approximately 142 million square feet as of September 30, 2020.

W.P. Carey REIT’s sales growth this year is anticipated to be 5.7% and 13.2% for next year.

Year-on-year quarterly revenue growth grew by 9%, now sitting on 1.31B for the twelve trailing months.

Volume

Today’s last reported volume for W.P. Carey REIT is 1369040 which is 24.18% above its average volume of 1102410.

W.P. Carey REIT’s sales growth for the next quarter is 11.8%. The company’s growth estimates for the present quarter and the next is a negative 37.3% and negative -40.5%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.07%.

Volatility

W.P. Carey REIT’s last day, last week, and last month’s current intraday variation average was 1.78%, 1.33%, and 1.18%, respectively.

W.P. Carey REIT’s highest amplitude of average volatility was 3.79% (day), 2.86% (last week), and 2.12% (last month), respectively.

W.P. Carey REIT’s Stock Yearly Top and Bottom Value

W.P. Carey REIT’s stock is valued at $85.43 at 16:22 EST, below its 52-week high of $86.48 and way above its 52-week low of $73.02.

W.P. Carey REIT’s Moving Average

W.P. Carey REIT’s worth is above its 50-day moving average of $82.11 and higher than its 200-day moving average of $79.08.

6. AutoNation (AN)

10.8% sales growth and 54.01% return on equity

AutoNation, Inc., via its subsidiaries, is an American automotive retailer.

AutoNation’s sales growth this year is expected to be 8.3% and 4.6% for next year.

Year-on-year quarterly revenue growth grew by 14.4%, now sitting on 26.69B for the twelve trailing months.

Volume

Today’s last reported volume for AutoNation is 1883630 which is 100.68% above its average volume of 938612.

AutoNation’s sales growth for the next quarter is 10.8%. The company’s growth estimates for the current quarter and the next is 26.7% and 15%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 54.01%.

Volatility

AutoNation’s last day, last week, and last month’s current intraday variation average was 5.60%, 5.28%, and 2.46%, respectively.

AutoNation’s highest amplitude of average volatility was 6.46% (day), 6.01% (last week), and 4.48% (last month), respectively.

AutoNation’s Stock Yearly Top and Bottom Value

AutoNation’s stock is valued at $110.64 at 16:22 EST, way below its 52-week high of $133.48 and way higher than its 52-week low of $89.25.

AutoNation’s Moving Average

AutoNation’s value is under its 50-day moving average of $114.47 and under its 200-day moving average of $114.86.

7. TriMas Corporation (TRS)

10.3% sales growth and 9.5% return on equity

TriMas Corporation produces and supplies products worldwide for the consumer, industrial, and aerospace markets.

TriMas Corporation’s sales growth this year is anticipated to be 9.5% and 5.5% for next year.

Year-on-year quarterly revenue growth grew by 8.5%, now sitting on 874.69M for the twelve trailing months.

Volume

Today’s last reported volume for TriMas Corporation is 96644 which is 25.05% below its average volume of 128955.

TriMas Corporation’s sales growth for the next quarter is 10.3%. The company’s growth estimates for the current quarter and the next is a negative 3.2% and 10.5%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.5%.

Volatility

TriMas Corporation’s last day, last week, and last month’s current intraday variation average was 2.22%, 1.60%, and 1.58%, respectively.

TriMas Corporation’s highest amplitude of average volatility was 1.67% (day), 2.63% (last week), and 3.08% (last month), respectively.

TriMas Corporation’s Stock Yearly Top and Bottom Value

TriMas Corporation’s stock is valued at $28.33 at 16:22 EST, way below its 52-week high of $38.72 and higher than its 52-week low of $26.06.

TriMas Corporation’s Moving Average

TriMas Corporation’s worth is below its 50-day moving average of $29.57 and way under its 200-day moving average of $32.44.

8. ESCO Technologies (ESE)

8.8% sales growth and 6.29% return on equity

ESCO Technologies Inc. manufactures and supplies engineered products for commercial, utility and industrial users around the world.

ESCO Technologies’s sales growth this year is anticipated to be 11.1% and 5.9% for next year.

Year-on-year quarterly revenue growth grew by 23.5%, now sitting on 768.81M for the twelve trailing months.

Volume

Today’s last reported volume for ESCO Technologies is 227902 which is 87.71% above its average volume of 121409.

ESCO Technologies’s sales growth is a negative 0% for the ongoing quarter and 8.8% for the next. The company’s growth estimates for the ongoing quarter and the next is 23.9% and 32.9%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.29%.

Volatility

ESCO Technologies’s last day, last week, and last month’s current intraday variation average was 1.15%, 2.63%, and 1.34%, respectively.

ESCO Technologies’s highest amplitude of average volatility was 3.32% (day), 3.52% (last week), and 2.60% (last month), respectively.

ESCO Technologies’s Stock Yearly Top and Bottom Value

ESCO Technologies’s stock is valued at $62.85 at 16:22 EST, way below its 52-week high of $97.55 and above its 52-week low of $60.03.

ESCO Technologies’s Moving Average

ESCO Technologies’s value is under its 50-day moving average of $64.87 and way below its 200-day moving average of $76.92.

LEAVE A REPLY

Please enter your comment!
Please enter your name here